

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**石四藥集團有限公司**  
**SSY Group Limited**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2005)**

**VOLUNTARY ANNOUNCEMENT**  
**UPDATE ON PRODUCT DEVELOPMENT**

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group’s Salbutamol Sulfate has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market.

Salbutamol Sulfate is mainly used in treatment of bronchial asthma, asthmatic bronchitis, and bronchospasm in patients with emphysema.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board  
**Chow Hing Yeung**  
*Executive Director and Company Secretary*

Hong Kong, 15 September 2023

*As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.*